Aridol (mannitol inhalation powder), is indicated for the assessment of bronchial hyperresponsiveness in patients 6 years and over who do not have clinically apparent asthma.
Limitations of Use:
Aridol is not a stand-alone test or a screening test for asthma. Bronchial challenge testing with Aridol should be used only as part of a physician’s overall assessment of asthma.
Aridol is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see Dosage Forms, Strengths, Composition and Packaging.
Aridol should not be given to patients with conditions that may be compromised by induced bronchospasm or repeated spirometry manoeuvres.
- aortic or cerebral aneurysm
- uncontrolled hypertension
- myocardial infarction or a cerebral vascular accident